• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2022.17091

Impact of anticancer therapy on the dynamics of myocardial damage markers, indicators of endothelial dysfunction and oxidative stress in patients with lymphomas

[Original research] [Oncology]
Olga Nikolaevna Antyufeeva; Darya Aleksandrovna Budanova; Irina Sergeevna Ilgisonis; Yuri Nikitich Belenkov; Vladimir Igorevich Ershov; Igor Yurievich Gadaev; Olga Valentinovna Bochkarnikova; Irina Yakovlevna Sokolova;

The study was carried out to assess the dynamics of TnI, hs-cTnI, H-FABP, NT-proBNP, SOD, MPO, VCAM in 105 patients with newly diagnosed lymphomas during of anticancer therapy. These indicators were evaluated initially (T1), 6 hours after the administration of anthracyclines (T2), after treatment course conclusion (T3). The structural and functional state of small vessels were determined by digital photoplethysmography (PPG). During PCT specific changes were observed: a significant increase in the level of NT-proBNP; significant decrease in the VCAM level; a downward tendency for H-FABP; an increase in MPO and SOD levels initially with a downward tendency during treatment, remaining above the reference values; improvement of microvasculature wall state due to PPG results. The obtained data has indicated the progression of myocardial dysfunction during antitumor therapy, activation of OS, and relative improvement in endothelial function. The study revealed the highest sensitivity for NT-proBNP in assessing the cardiotoxic effect of PCT from the first stages of treatment. The results of the dynamics of H-FABP, VCAM, MPO, SOD levels may also indicate the probable participation of LPD itself in the development of ED and OS in these patients.

Download

References:
1. Bowzyk Al-Naeeb A., Ajithkumar T., Behan S., Hodson D. J. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204. https://doi.org/10.1136/bmj.k3204
2. Snipelisky D., Park J. Y., Lerman A., Mulvagh S., Lin G. [et al.]. How to Develop a Cardio-Oncology Clinic. Heart Fail. Clin. 2017;13(2):347-359. https://doi.org/10.1016/j.hfc.2016.12.011
3. Curigliano G., Lenihan D., Fradley M., Ganatra S., Barac A. [et al.]. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 2020;31(2):171-190. https://doi.org/10.1016/j.annonc.2019.10.023
4. Abe J.-I., Sood A. K., Martin J. F. Editorial: Cardio Oncology: From Bench to Bedside. Front. Cardiovasc. Med. 2019;6:37. https://doi.org/10.3389/fcvm.2019.00037
5. Grakova E. V., Shilov S. N., Kopeva K. V., Berezikova E. N., Popova A. A. [et al.]. Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction. Cardiology.2021;146(3):315-323. https://doi.org/10.1159/000512771
6. Ndrepepa G. Myeloperoxidase – A bridge linking inflammation and oxidative stress with cardiovascular disease. Clin. Chim. Acta. 2019;493:36-51. https://doi.org/10.1016/j.cca.2019.02.022
7. Antyufeeva O. N., Budanova D. A., Ilgisonis I. S., Gadaev I. Yu., Bochkarnikova O. V. [et al.]. Assessment of the Dynamics of Oxidative Stress Indicators and Early Markers of Myocardial Damage and Dysfunction in Patients with Aggressive Lymphoproliferative Diseases During of Anticancer Therapy. Kardiologiia. – Cardiology. 2020;60(12):76-82. (In Russ.). https://doi.org/10.18087/cardio.2020.12.n1394
8. Budanova D. A., Antyufeeva O. N., Ilgisonis I. S., Sokolova I. Ya., Belenkov Yu. N. [et al.]. Assessment of the dynamics of direct damage and myocardial dysfunction, indicators of endothelial dysfunction in patients with indolent lymphomas before and after anticancer therapy. Kardiologiia. – Cardiology. 2020;60(11):49-56. (In Russ.). https://doi.org/10.18087/cardio.2020.11.n1390
9. Yvonne Alexander, Elena Osto, Arno Schmidt-Trucksäss, Michael Shechter, Danijela Trifunovic [et al.]. Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovascular Research. 2021;117(1):29-42. https://doi.org/10.1093/cvr/cvaa085
10. Goel H., Melot J., Krinock M. D., Kumar A., Nadar S. K. [et al.]. Heart-type fatty acid-binding protein: an overlooked cardiac biomarker. Ann. Med. 2020;52(8):444-461. https://doi.org/10.1080/07853890.2020.1800075
11. Ponikowski P., Voors A. A., Anker S. D., Bueno H., Cleland J. G. [et al.]. Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart. Fail. 2016;18(8):891-975. https://doi.org/10.1002/ejhf.592
12. Pudil R., Mueller C., Čelutkienė J., Henriksen P. A., Lenihan D. [et al.]. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur. J. Heart. Fail.2020;22(11):1966-1983. https://doi.org/10.1002/ejhf.2017
13. Fringu F. I., Sitar-Taut A. V., Caloian B., Zdrenghea D., Comsa D. [et al.]. The role of NTproBNP in the evalution of diabetic patients with heart failure. Acta Endocrinol. (Buchar). 2020;16(2):183-191. https://doi.org/10.4183/aeb.2020.183
14. Robert A. Lewis, Charlotte Durrington, Robin Condliffe, David G. Kiely. BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing. Eur. Resp. Rev. 2020;29(156):200009. https://doi.org/10.1183/16000617.0009-2020
15. Blix E. S., Husebekk A. Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies. Leukemia & Lymphoma. 2016;57(12):275-2762. https://doi.org/10.1080/10428194.2016.1201566
16. Syrigos K. N., Salgami E., Karayiannakis A. J., Katirtzoglou N., Sekara E. [et al.]. Prognostic significance of soluble adhesion molecules in Hodgkin’s disease. Anticancer Res. 2004;24(2C):1243-1247.
17. Schahab N., Mansuroglu S., Schaefer C., Fimmers R.,Nickenig G. [et al.]. Prognostic value of myeloperoxidase in patients with peripheral artery disease. Vascular. 2021;29(3):363-371. https://doi.org/10.1177/1708538120957491
18. Demissei B. G., Hubbard R. A., Zhang L., Smith A. M., Sheline K. [et al.]. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J. Am. Heart Assoc. 2020;9(2):e014708. https://doi.org/10.1161/JAHA.119.014708
19. Sultan A., Wörmann J., Lüker J., Bruck J.-H. V. D., Plenge T. [et al.]. Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response. Clin. Res. Cardiol. 2020. https://doi.org/10.1007/s00392-020-01690-1
20. Hage C., Michaëlsson E., Kull B., Miliotis T., Svedlund S. [et al.]. Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. ESC Heart Fail. 2020;7(4):1534-1546. https://doi.org/10.1002/ehf2.12700
21. Younus H. Therapeutic potentials of superoxide dismutase. Int. J. Health Sci. (Qassim). 2018;12(3):88-93.
22. Ajikumar A., Long M. B., Heath P. R., Wharton S. B., Ince P. G. [et al.]. Neutrophil-Derived Microvesicle Induced Dysfunction of Brain Microvascular Endothelial Cells In Vitro. Int. J. Molec. Sci. 2019;20(20):5227. https://doi.org/10.3390/ijms2020522724

Keywords: lymphoma, antitumor therapy, cardiotoxicity, endothelial dysfunction, oxidative stress, biomarkers